Research analysts at StockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Free Report) in a note issued to investors on Friday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Genocea Biosciences Price Performance
The company has a market capitalization of $6,000.00, a PE ratio of 0.00 and a beta of 1.61. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.24. Genocea Biosciences has a twelve month low of $0.00 and a twelve month high of $0.00.
About Genocea Biosciences
Further Reading
- Five stocks we like better than Genocea Biosciences
- How to Start Investing in Real Estate
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- 3 Ways To Invest In Coffee, Other Than Drinking It
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Find and Profitably Trade Stocks at 52-Week Lows
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.